Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy Non STE ACS
Advertisements

Unstable Angina: Embolism Can Occur Prior to PCI Thrombus in proximal RCA Stain of muscle before injection begins: TIMI Myocardial perfusion grade 1 CM.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Update on the Medical Management of Acute Coronary Syndrome.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
lopidogrel in nstable Angina to Prevent ecurrent vents
ACUTE CORONARY SYNDORME EARLY RISK STRATIFICATION Sarah Jamison March 2003.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
Primary PCI Treatment of choice for Acute MI.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Unstable Angina /Non-ST Elevation Myocardial Infarction Critical Pathway Toolkit Adapted from Dr Chris Cannon STRIVE Scientific Committee – 2008 Based.
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
1 DIAGNOSTICS OF Acute Coronary Syndromes At the end of this self study the participant will: Verbalize meanings of specific ECG changes: –ST Elevation.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
Number Needed to Treat. End Points Baseline Risk is the risk associated with a particular condition Baseline Risk is the risk associated with a particular.
New Treatment Advances in Acute Coronary Syndrome.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Empiric Management of ACS With GP IIb/IIIa Platelet Receptor Blockers.
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
Enoxaparin – Future Prospects in Cardiovascular Diseases David Hasdai, MD Rabin Medical Center Tel Aviv University.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Acute Coronary Syndromes SIGN 93. MINAP Mortality after Acute Coronary Syndromes Cumulative: 13.6% Blue 10.6% Green 11.6% Red.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.
Antiplatelet Interventions in Acute Coronary Syndromes.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
LESSON 1 LESSON 1 Establishment of:
GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.
PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: A guide to therapeutic decision-making in patients.
Management Strategies for Post-Intervention in Patients with CAD VBWG.
Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
Women and Cardiovascular Disease
Prehospital NSTEMI Patient Assessment and Treatment
Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:
Revascularization in Patients With Left Ventricular Dysfunction:
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Management of ST-Elevation Myocardial Infarction
Clinical need for determination of vulnerable plaques
This series of slides highlights a report on a symposium at the European Society of Cardiology Congress held in Munich, Germany from August 28 to September.
European Heart Association Journal 2007 April
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Preventive Angioplasty in Myocardial Infarction Trial
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
Global Registry of Acute Coronary Events: GRACE
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
What oral antiplatelet therapy would you choose?
SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
European Heart Journal Advance Access
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
GUSTO 1 Trial 41,000 patients enrolled, landmark study
Cardiovascular Epidemiology and Epidemiological Modelling
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry annually

Current Management Goals in Treating Acute Coronary Syndromes Presumed prognosis: very high risk of in-hospital death Treatment goal: prevent death by restoring coronary blood flow Fibrinolytic therapy Direct PCI Presumed prognosis: low risk of in-hospital death, unless MI develops Treatment goal: stabilize with aspirin heparin & monitor for MI development + Cardiac enzymes – Cardiac Enzymes Scheduled PCI Manage medically Low - risk features High- risk features

1.0%  ( P  0.001) 1.9%  ( P  0.01) 11.5% 9.6% 7.3% 6.3% Heparin % death at 30 days (n=60,000) 1 (n=30,647) 2 Pooled thrombolytics Accelerated alteplase Streptokinase 1. Fibrinolytic therapy trialists’ collaborative group et al. Lancet.1994; 343: The GUSTO investigators. N Engl Med. 1993; 329: Reduction in Mortality Associated with Fibrinolytic Therapy for ST Elevation MI

6-month Mortality for Acute Coronary Syndromes T-wave inversion ACS ST  ACS Granger CB et al. J Am Coll Cardiol. 1998; 31:79A. % Cumulative mortality at 6 months ST  MI with fibrinolytics

Incidence of Adverse Outcomes in Non-ST Elevation ACS Patients Treated with Aspirin Plus Heparin Incidence of death or (re)MI 9.8% 3.2% 1.9% 1.7% 1.9% 2.9% 0-7 days  7-30 days > days Greenbaum AB et al. Circulation. 1998; Suppl I: I-630 Cumulative mortality rate: 1.7% Cumulative mortality rate: 3.6% Cumulative mortality rate: 6.5%

18.3% 5.5% 12.8%  (P=0.0001) Patients with MI within 72 hours (n=593) Patients without MI within 72 hours (n=8,868) Days following randomization % cumulative mortality Cumulative Mortality in Patients Experiencing MI During Hospitalization for Non-ST Elevation ACS Fintel DJ et al. J Am Coll Cardiol. 2000; 35A: A

3.9% 8.0% 9.0% 10.9% 14.9% 20.9% Normal  1-2 *  2-3 *  3-5 *  5-10 *  10* % Congestive Heart Failure/ Cardiogenic Shock at 30 days * x upper limit of normal 4.9% 5.7% 9.2% 12.6% 14.5% 19.9% % Death at 6 months Relationship Between Extent of Myocardial Necrosis and Long-Term Morbidity and Mortality (n=5,681)(n=1,098)(n=294)(n=302)(n=249)(n=211) Alexander JH et al. Circulation. 1999; Suppl 1: CK-MB levels during hospitalization Normal  1-2 *  2-3 *  3-5 *  5-10 *  10 * CK-MB levels during hospitalization

Incidence of MI Prior to PCI in Patients with Non-ST Elevation ACS 8.9% 2.2% PCI within 2-3 days PCI within 24 hours % MI prior to PCI Roe MT, et al. J Am Coll Cardiol. 2000; 35: 40A. Post-randomization analysis

Cumulative Mortality at 6 Months in Patients Experiencing MI Prior to PCI 15.2% 3.5% 11.7%  (P=0.001) No MI prior to early PCI (n=1,204) MI prior to early PCI (n=46) Months following randomization % cumulative mortality Post-randomization analysis Fintel DJ et al. J Am Coll Cardiol. 2000; 35A: A375.

ST  49% Mixed ST  & ST  20% T-wave inversion 31% % Patients with non-ST  ACS ST Depression is The Most Common ECG Abnormality Noted in Patients Presenting with Non-ST Elevation ACS Savonitto S, et al. J Am Med Assoc. 1999; 281:

% 8% 6% 4% 2% T-wave inversion 3.4% ST  6.8% ST  8.9% Days from randomization % Cumulative Mortality 2 ST Depression: Indicates Increased Risk for Long-term Mortality Savonitto S, et al. J Am Med Assoc. 1999; 281:

Patients with ST  : Likely to Have Higher-risk Medical Histories than Patients with ST  Savonitto S, et al. J Am Med Asoc. 1999; 281:

ST Depression Signifies Likelihood to Require High-risk Revascularization Savonitto S, et al. J Am Med Asoc. 1999; 281:

Percent of Patients Presenting with Non-ST Elevation ACS who Present with Elevated CK or CK-MB Lab Values The PURSUIT trial investigators. N Engl J Med. 1998; 339: The PRISM-PLUS investigators. N Engl J Med. 1998; 338: The TIMI IIIb investigators. Circulation. 1996; 335:

Relationship Between Elevated Cardiac Enzymes at Presentation and Long-term Risk for Death or (re)MI 19.0% 13.0% 13.1% 8.9%  CK-MB (n=4,308)  CK-MB (n=921) Normal CK-MB (n=5,129) Normal CK-MB (n=7,438) PURSUIT 1 GUSTO IIb 2 % death or (re)MI at 30 days 1,2 1. The PURSUIT trial investigators. N Engl J Med. 1998; 339: Savonitto S, et al. J Am Med Asoc. 1999; 281:

Correlation Between Elevated Cardiac Enzymes at Presentation and Long-term Mortality + Cardiac Troponin T at Baseline (n=559) 14.1% 4.5% – Cardiac Troponin T at Baseline (n=474) % mortality at 1 year Newby LK et al. Circulation. 1998; 98: P<0.0001

Relationship Between Degree of Troponin Elevation and Likelihood for Long-term Mortality Antman EM, it al. N Engl J Med. 1996; 335: % mortality at 42 days <0.4<1.0<2.0<5.0<9.0  Troponin levels

Risk of Death/Re-MI in Patients Presenting with ST  and Elevated Cardiac Enzymes at Presentation 14.8% 8.0% 21.7% 14.6% ST  with CK-MB  ST  with normal CK % death % death + re-MI Events at 6 months Savonitto S, et al. J Am Med Asoc. 1999; 281: ST  with CK-MB  ST  with normal CK

Predictors of Increased Risk of Death or MI at 30 Days from the PURSUIT Study The PURSUIT trial investigators. N Engl J Med. 1998; 339: